(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 June 2014 (26.06.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/096145 A1

(51) International Patent Classification:
A61K 38/26 (2006.01) *C07K 14/605* (2006.01)

(21) International Application Number:
PCT/EP2013/077307

(22) International Filing Date:
19 December 2013 (19.12.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12306647.4 21 December 2012 (21.12.2012) EP

(71) Applicant: **SANOFI** [FR/FR]; 54 rue La Boétie, F-75008 Paris (FR).

(72) Inventors: **HAACK, Torsten**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WAGNER, Michael**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **HENKEL, Bernd**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **STENGELIN, Siegfried**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **EVERS, Andreas**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **LORENZ, Martin**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **LORENZ, Katrin**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).

(74) Agents: **WEISS, Wolfgang** et al.; Weickmann & Weickmann, Richard-Strauss-Str. 80, 81679 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2014/096145 A1

(54) Title: EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS

(57) Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.